Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation

This phase 2 trial tests a personalized approach for people with newly diagnosed, advanced classical Hodgkin lymphoma. After two cycles of standard chemotherapy, patients are grouped based on a PET scan. Those with a moderate response receive the immunotherapy drug sintilimab plus a milder chemotherapy, aiming to avoid high-dose chemotherapy and radiation. The study will track how well this strategy controls the cancer and whether it reduces side effects.